PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Marcelo V,Negrao

第一单位： Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

作者： Marcelo V,Negrao ^[1] ; Vincent K,Lam ^[1] ; Alexandre,Reuben ^[1] ; Maria Laura,Rubin ^[2] ; Lara Lacerda,Landry ^[1] ; Emily B,Roarty ^[1] ; Waree,Rinsurongkawong ^[1] ; Jeff,Lewis ^[2] ; Jack A,Roth ^[3] ; Stephen G,Swisher ^[3] ; Don L,Gibbons ^[1] ; Ignacio I,Wistuba ^[4] ; Vassiliki,Papadimitrakopoulou ^[1] ; Bonnie S,Glisson ^[1] ; George R,Blumenschein ^[1] ; J Jack,Lee ^[2] ; John V,Heymach ^[1] ; Jianjun,Zhang ^[5]

作者单位： Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. ^[1] Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. ^[2] Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. ^[3] Department of Translational Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. ^[4] Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Electronic address: jzhang20@mdanderson.org. ^[5]

关键词 HLA class I Immunotherapy Lung cancer PD-L1 Tumor mutational burden